imported>Bestem |
imported>Kristina.jozic |
| (12 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| ==Prophylaxe/Prävention== | | ======Endokarditis-Prophylaxe====== |
| '''<span style="color: #333333">Endokarditis-Prophylaxe</span>'''
| |
| '''<span style="color: #333333">Grundlage:</span>'''
| |
|
| |
|
| * <span style="color: #333333">2015 ESC Guidelines for the management of infective Endocarditis</span> | | *Grundlage |
| * <span style="color: #333333">ask</span> <span style="color: #333333"><span style="letter-spacing:-.1pt">force</span> for the Management <span style="letter-spacing:-.1pt">of</span> Infective Endocarditis <span style="letter-spacing:-.1pt">of</span> the European <span style="letter-spacing:.05pt">Society</span> <span style="letter-spacing: -.1pt">of</span> <span style="letter-spacing:-.05pt">Cardiology</span></span> | | **2023 ESC Guidelines for the management of infective Endocarditis |
| | **Task force for the Management of Infective Endocarditis of the European Society of Cardiology |
| | *Wer: |
| | **Wird nur für Hochrisikopatient:innen empfohlen {{Tooltip|text=Hochrisikopatient:innen sind Patient:innen mit der höchsten Inzidenz einer infektiösen Endokarditis und/oder mit dem höchsten Risiko für einen schlechten Verlauf einer infektiösen Endokarditis.}}Dazu gehören: |
| | **Patient:innen mit chirurgisch implantierten Herzklappenprothesen und mit jedweden Materialien, die zur chirurgischen Herzklappenrekonstruktion verwendet werden |
| | **Patient:innen mit kathetergestützter Implantation einer Aorten- oder Pulmonalklappenprothese |
| | **Patient:innen mit überstandener Endokarditis |
| | **unbehandelte zyanotischen angeborenen Herzfehlern und bei Patienten, die chirurgisch oder mittels kathetergestützte Verfahren mit postoperativen palliativen Shunts, Conduits oder anderen Prothesen behandelt werden |
|
| |
|
| '''Wer:'''
| | Wenn nach chirurgischer Rekonstruktion keine Restdefekte oder Klappenprothesen vorhanden sind, wird eine Antibiotikaprophylaxe nur für die ersten 6 Monate nach dem Eingriff empfohlen |
|
| |
|
| * wird nur für Hochrisikopatienten empfohlen | | *bei Patient:innen mit ventrikulären Unterstützungssystemen |
| * Hochrisikopatienten sind <span style="letter-spacing:-.1pt">Patienten</span> <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.1pt">der</span> höchsten <span style="letter-spacing:.05pt">Inzidenz</span> einer infektiösen <span style="letter-spacing:-.05pt">Endokarditis</span> <span style="letter-spacing: -.2pt">und/oder</span> <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.05pt">dem</span> höchsten <span style="letter-spacing:.05pt">Risiko</span> <span style="letter-spacing: .1pt">für</span> einen schlechten <span style="letter-spacing:-.2pt">Verlauf</span> einer infektiösen <span style="letter-spacing:-.05pt">Endokarditis.</span> Dazu <span style="letter-spacing:-.05pt">gehören:</span> | | *bei Patient:innen mit kathetergestützter Mitral- und Trikuspidalklappenrekonstruktion '''sollte eine Endokarditis-Prophylaxe erwogen werden ''' |
| * Patienten mit Klappenprothesen, einschließlich Transkatheterklappen, oder mit rekonstruierten Klappen unter Verwendung prothetischen Materials
| | *bei herztransplantierten Patient:innen '''kann eine Endokarditis-Prophylaxe erwogen werden''' |
| * Patienten <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.05pt">überstandener</span> <span style="letter-spacing: -.05pt">Endokarditis</span> | |
| * Patienten mit angeborenen Herzfehlern:
| |
|
| |
|
| # jegliche zyanotischen Herzfehler
| | Keine Endokarditis-Prophylaxe für alle anderen Patient:innen mit geringem Risiko für eine infektiöse Endokarditis |
| # bis zu 6 Monate nach operativer oder interventioneller Vitienkorrektur unter Verwendung von prothetischem Material oder lebenslang bei residuellem Shunt oder Klappeninsuffizienz
| |
|
| |
|
| * Keine Endokarditis-Prophylaxe <span style="letter-spacing:.1pt">für</span> alle <span style="letter-spacing:-.05pt">anderen</span> <span style="letter-spacing: -.05pt">Formen</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">Klappen-</span> <span style="letter-spacing: .05pt">und</span> Herzerkrankungen | | *Wann{{Tooltip|text=(bei welchen Eingriffen sollten Hochrisikopatient:innen eine Endokarditis-Prophylaxe erhalten)}}: |
| | **Zahnärztliche Eingriffe |
| | ***Endokarditis-Prophylaxe empfohlen bei Zahnextraktionen, oralchirurgische Eingriffen, Eingriffen/ Manipulationen an der Gingiva, der periapikalen Zahnregion |
| | **invasive diagnostische oder therapeutische Verfahren in den Bereichen der Atemwege, Ohren, Magen-Darm-Trakt, Urogenitaltrakt, Haut oder Bewegungsapparat |
| | ***Endokarditis-Prophylaxe kann bei Hochrisikopatient:innen erwogen werden |
|
| |
|
| '''Wann''' (bei welchen Eingriffen sollten Hochrisikopatienten eine Endokarditis-Prophylaxe erhalten):
| | ======PAP und Endokarditis-Prophylaxe====== |
| | | Liegt eine Indikation zur Endokarditis-Prophylaxe vor, werden - anstelle der oben empfohlenen Antibiotika – bevorzugt Substanzen mit Enterokokken-Wirksamkeit eingesetzt: |
| * Zahnärztliche Eingriffe
| |
| | |
| o Endokarditis-Prophylaxe <span style="letter-spacing:-.05pt">empfohlen</span> <span style="letter-spacing:-.05pt">bei</span> <span style="letter-spacing:.05pt">Eingriffen</span> / <span style="letter-spacing:-.05pt">Manipulationen</span> <span style="letter-spacing:.1pt">an</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">Gingiva,</span> <span style="letter-spacing:
| |
| -.1pt">der</span> periapikalen <span style="letter-spacing:.05pt">Zahnregion</span> <span style="letter-spacing:
| |
| -.05pt">oder</span> <span style="letter-spacing:-.1pt">Perforation</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">oralen</span> <span style="letter-spacing:-.05pt">Mukosa</span>
| |
| | |
| o KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span> <span style="letter-spacing:-.05pt">bei</span> <span style="letter-spacing:-.05pt">Applikation</span> <span style="letter-spacing:-.15pt">von</span> Lokalanästhesie <span style="letter-spacing:.1pt">in</span> reizlosem <span style="letter-spacing:-.1pt">Gewebe,</span> <span style="letter-spacing:
| |
| -.1pt">Faden-</span> entfernung, <span style="letter-spacing:-.1pt">Röntgen,</span> Einsatz <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing:
| |
| -.05pt">Entfernung</span> <span style="letter-spacing:-.15pt">von</span> Zahnprothesen <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing:
| |
| .05pt">Klammern,</span> <span style="letter-spacing:-.05pt">Lippentrauma</span> <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing:-.1pt">Verletzung</span> <span style="letter-spacing:
| |
| -.1pt">der</span> <span style="letter-spacing:-.05pt">oralen</span> <span style="letter-spacing:-.05pt">Mukosa</span>
| |
| | |
| o KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span> nach <span style="letter-spacing:.05pt">Milchzahnwechsel</span> <span style="letter-spacing:-.05pt">oder</span> <span style="letter-spacing:
| |
| -.1pt">Verletzung</span> <span style="letter-spacing:-.1pt">der</span> <span style="letter-spacing:-.05pt">Lippen</span> <span style="letter-spacing:
| |
| .05pt">und</span> <span style="letter-spacing:-.05pt">oralen</span> <span style="letter-spacing:-.05pt">Mukosa</span>
| |
| | |
| * Eingriffe am Respirationstrakt
| |
| | |
| '''Cave:''' KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span> <span style="letter-spacing:-.05pt">bei</span> Eingriffen am Respirationstrakt, einschließlich <span style="letter-spacing:-.05pt">Laryngoskopie,</span> <span style="letter-spacing:-.1pt">Bronchoskopie</span> transnasale-,
| |
| | |
| * <span style="letter-spacing:-.05pt">endotracheale</span> <span style="letter-spacing:-.05pt">Intubation (oral oder nasal)</span>
| |
| * Gastrointestinale oder Urogenitale Eingriffe an infizierten Herden
| |
| | |
| o intraabdominaler Abszess
| |
| | |
| o Ileus
| |
| | |
| o Darmperforation
| |
| | |
| o Magenperforation
| |
| | |
| o Cholecystitis/ Gallenblasenempyem
| |
| | |
| o Fourniersche Gangrän
| |
| | |
| o infizierte Harnstauungsniere
| |
| | |
| '''Cave:''' KEINE <span style="letter-spacing:
| |
| -.05pt">Endokarditis-Prophylaxe</span> <span style="letter-spacing:-.05pt">bei</span><span style="letter-spacing:.05pt">:</span> <span style="letter-spacing:-.1pt">Gastroskopie,</span> <span style="letter-spacing:-.15pt">Coloskopie,</span> transösophageales <span style="letter-spacing:-.1pt">Echo,</span> <span style="letter-spacing:-.1pt">Cystoskopie</span>
| |
| | |
| * Eingriffe an Weichteilgewebe und Haut
| |
| | |
| o KEINE <span style="letter-spacing:-.05pt">Endokarditis-Prophylaxe</span>
| |
| | |
| '''PAP und Endokarditis-Prophylaxe'''
| |
| | |
| Liegt eine Indikation zur Endokarditis-Prophylaxe vor, <span style="letter-spacing:-.1pt">werden</span> - anstelle <span style="letter-spacing:-.1pt">der</span> oben <span style="letter-spacing: | |
| -.05pt">empfohlenen</span> Antibiotika – <span style="letter-spacing:
| |
| -.05pt">bevorzugt</span> Substanzen <span style="letter-spacing:-.05pt">mit</span> <span style="letter-spacing:-.05pt">Enterokokken-Wirksamkeit</span> eingesetzt:
| |
| {| class="wikitable" | | {| class="wikitable" |
| |+ | | |+ |
| !'''Antibiotika zur PAP''' | | !Antibiotika zur PAP |
| !Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe<br /> | | !Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe<br /> |
| |- | | |- |
| |Ohne <span style="letter-spacing:-.15pt">P</span><span style="letter-spacing:-.1pt">AP-Indikation</span><br /> | | |Ohne PAP-Indikation |
| |Ampicillin 2g <span style="letter-spacing: | | |Ampicillin 2g i.v. |
| -.2pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span><br />
| |
| |- | | |- |
| |Cefazolin / <span style="letter-spacing: | | |Cefazolin / Cefuroxim |
| -.2pt">C</span><span style="letter-spacing:-.1pt">efuroxim</span><br />
| | |Ampicillin-Sulbactam 3g i.v. |
| |<span style="color: #222222">Ampicillin-</span><span style="color: #222222">Sulbac</span><span style="color: #222222">t</span><span style="color: #222222">am</span> <span style="color: #222222">3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span></span><br /> | |
| |- | | |- |
| |Cefazolin / <span style="letter-spacing: | | |Cefazolin / Cefuroxim + Metronidazol |
| -.2pt">C</span><span style="letter-spacing:-.15pt">ef</span><span style="letter-spacing:-.1pt">ur</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">xi</span><span style="letter-spacing:-.15pt">m</span> + <span style="letter-spacing:-.15pt">Me</span><span style="letter-spacing:-.1pt">tr</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">nid</span><span style="letter-spacing:-.15pt">az</span><span style="letter-spacing:-.1pt">ol</span><br />
| | |Ampicillin-Sulbactam 3g i.v. |
| |<span style="color: #222222">Ampicillin-</span><span style="color: #222222">Sulbac</span><span style="color: #222222">t</span><span style="color: #222222">am</span> <span style="color: #222222">3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span></span><br /> | |
| |} | | |} |
| {| class="wikitable" | | {| class="wikitable" |
| |+
| | !ß-Laktam-Allergie |
| !'''ß-Laktam-Allergie''' | |
| !Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe<br /> | | !Empfohlene (Ersatz-) Substanz bei Indikation zur Endokarditis-Prophylaxe<br /> |
| |- | | |- |
| |Ohne <span style="letter-spacing:-.15pt">P</span><span style="letter-spacing:-.1pt">AP</span><br /> | | |Ohne PAP |
| |<span style="color: #222222">Cli</span><span style="color: #222222">ndam</span><span style="color: #222222">y</span><span style="color: #222222">cin</span> <span style="color: #222222">600m</span><span style="color: #222222">g</span> <span style="color: #222222">i.</span><span style="color: #222222">v</span><span style="color: #222222">./p.o.</span><br /> | | |Clindamycin 600mg i.v./p.o |
| |- | | |- |
| |Cefazolin / <span style="letter-spacing: | | |Cefazolin / Cefuroxim (ohne Gastrointestinaltrakt) |
| -.2pt">C</span><span style="letter-spacing:-.1pt">efuroxim (ohne Gastrointestinaltrakt)</span><br />
| | |Clindamycin 600mg i.v./p.o |
| |<span style="color: #222222">Cli</span><span style="color: #222222">ndam</span><span style="color: #222222">y</span><span style="color: #222222">cin</span> <span style="color: #222222">600m</span><span style="color: #222222">g</span> <span style="color: #222222">i.</span><span style="color: #222222">v</span><span style="color: #222222">./p.o.</span><br /> | |
| |- | | |- |
| |Cefazolin / <span style="letter-spacing: | | |Cefazolin / Cefuroxim +/- Metronidazol |
| -.2pt">C</span><span style="letter-spacing:-.15pt">ef</span><span style="letter-spacing:-.1pt">ur</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">xi</span><span style="letter-spacing:-.15pt">m</span> +/- <span style="letter-spacing:-.15pt">Me</span><span style="letter-spacing:-.1pt">tr</span><span style="letter-spacing:-.15pt">o</span><span style="letter-spacing:-.1pt">nid</span><span style="letter-spacing:-.15pt">az</span><span style="letter-spacing:-.1pt">ol</span><br />
| | |Vancomycin 1g i.v. + Ciprofloxacin 400 mg i.v. +/- Metronidazol 500 mg i.v. |
| |Vancomycin 1g <span style="letter-spacing: | |
| -.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> + <span style="letter-spacing:-.2pt">C</span><span style="letter-spacing:-.1pt">ipr</span><span style="letter-spacing:-.15pt">ofloxacin</span> 400 <span style="letter-spacing:-.1pt">mg</span> <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> +/- <span style="letter-spacing:-.15pt">Me</span><span style="letter-spacing:-.1pt">t</span><span style="letter-spacing:-.15pt">ro</span><span style="letter-spacing:-.1pt">nid</span><span style="letter-spacing:-.15pt">azol</span> 500 <span style="letter-spacing:-.1pt">mg</span> <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span><br />
| |
| |} | | |} |
| '''Antibiotika für die perioperative Antibiotika- und Endokarditis-Prophylaxe'''
| | |
| | [[Datei:DGI:Graphik perioperative Prophylaxe 1.png|zentriert|mini| https://leitlinien.dgk.org/files/10_2023_pocket_leitlinien_endokarditis.pdf]] |
| | |
| | |
| | ====== Antibiotika für die perioperative Antibiotika- und Endokarditis-Prophylaxe ====== |
| {| class="wikitable" | | {| class="wikitable" |
| |+
| |
| !'''Antibiotikagruppe''' | | !'''Antibiotikagruppe''' |
| !'''Substanz''' | | !'''Substanz''' |
| !'''Dosis/Applikations-art''' | | !'''Dosis/Applikations-art''' |
| | !'''Applikation als Infusion''' |
| !'''Zeitpunkt der Gabe''' | | !'''Zeitpunkt der Gabe''' |
| !'''Wiederholungsgabe<sup>3)</sup>''' | | !'''Intervall für 2.Dosis<sup>**</sup>''' |
| |- | | |- |
| |Aminopenicillin<br /> | | |Aminopenicillin<br /> |
| |Ampicillin<br /> | | |Ampicillin<br /> |
| |1 x 2g <span style="letter-spacing: | | |1 x 2g i.v. |
| -.2pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span><br />
| | | |
| |Infusionsende 30 min vor Schnitt<br /> | | |Infusionsende 30 min vor Schnitt<br /> |
| |> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | | |> 3 h OP-Dauer |
| |- | | |- |
| |<span style="color: #222222">Aminope</span><span style="color: #222222">nicillin</span> <span style="color: #222222">+</span> | | |Aminopenicillin + |
| | | ß-Lakt.-Inhibitor (BLI) |
| | | |Amoxicillin + Clavulan-Säure |
| <span style="color: #222222">ß</span><span style="color: #222222">-Lakt.-Inhibitor (BLI)</span>
| | Ampicillin + Sulbactam |
| |<span style="color: #222222">Amo</span><span style="color: #222222">xicillin</span> <span style="color: #222222">+ <span style="letter-spacing:-.1pt">Clav</span><span style="letter-spacing:-.05pt">ulan-Säure</span></span><br /><span style="color: #222222">Ampicillin</span> <span style="color: #222222">+ <span style="letter-spacing:-.1pt">Sulbac</span><span style="letter-spacing:-.05pt">t</span><span style="letter-spacing:-.1pt">am</span></span> | |
| |1 x 875/125mg p.o.<br />1 x 3g i.v. | | |1 x 875/125mg p.o.<br />1 x 3g i.v. |
| |120 <span style="letter-spacing: | | | |
| -.05pt">min vor Schnitt</span><sup>1)</sup><br />Infusionsende 30 min vor Schnitt
| | 30 min |
| |> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br />> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span> | | |120 min vor Schnitt<sup>*</sup> |
| | Infusionsende 30 min vor Schnitt |
| | |> 3 h OP-Dauer |
| | 2h |
| |- | | |- |
| |gezielte Carbapenem-Prophylaxe<br /> | | |gezielte Carbapenem-Prophylaxe<br /> |
| |Imipenem <sup>2)</sup> | | |Imipenem {{Tooltip|text=„Imipenem 1g“ entspricht Imipenem 1g + Cilastatin 1g (= 2x 1Ampulle à 0,5g Imipenem + 0,5g Cilastatin)}} |
| | |
| | |
| Meropenem | | Meropenem |
| |1 x 1g <span style="letter-spacing:-.2pt">i.</span><span style="letter-spacing:-.25pt">v</span> | | |1 x 1g i.v. |
| | |
| | |
| 1 x 1g i.v. | | 1 x 1g i.v. |
| | |30 min |
| |Infusionsende 30 min vor Schnitt<br /> | | |Infusionsende 30 min vor Schnitt<br /> |
| |> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | | | |
| | 2h |
| |- | | |- |
| |Cephalosporin Gruppe 1<br /> | | |Cephalosporin Gruppe 1<br /> |
| |Cefazolin<br /> | | |Cefazolin<br /> |
| |1 x 2g <span style="letter-spacing:-.2pt">i.</span><span style="letter-spacing:-.25pt">v</span> bei KG<br />>120<span style="letter-spacing: | | |1 x 2g i.v bei KG |
| -.15pt">kg</span> 1 x 3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span> | | ≥100-120kg 1 x 3g i.v. |
| | |30 min |
| |Infusionsende 30 min vor Schnitt<br /> | | |Infusionsende 30 min vor Schnitt<br /> |
| |> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | | |3-4h |
| |- | | |- |
| |Cephalosporin Gruppe 2<br /> | | |Cephalosporin Gruppe 2<br /> |
| |Cefuroxim<br /> | | |Cefuroxim<br /> |
| |1 x 1,5g <span style="letter-spacing: | | |1 x 1,5g i.v bei KG |
| -.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span>
| | ≥100-120kg 1 x 3g i.v. |
| | | |30 min |
| | |
| >120<span style="letter-spacing:-.15pt">kg</span> 1 x 3g <span style="letter-spacing:-.25pt">i.</span><span style="letter-spacing:-.3pt">v</span><span style="letter-spacing:-.25pt">.</span>
| |
| |Infusionsende 30 min vor Schnitt<br /> | | |Infusionsende 30 min vor Schnitt<br /> |
| |> 3 h <span style="letter-spacing:-.1pt">OP-Daue</span><span style="letter-spacing:-.05pt">r</span><br /> | | |3-4h |
| |} | | |} |
| '''Sonderindikationen'''
| | |
| | ====== Sonderindikationen ====== |
| {| class="wikitable" | | {| class="wikitable" |
| |+
| | !Antibiotikagruppe |
| !'''Antibiotikagruppe''' | | !Substanz |
| !'''Substanz''' | | !Dosis/Applikations-art |
| !'''Dosis/Applikations-art''' | | !Applikation als Infusion |
| !'''Zeitpunkt der Gabe''' | | !Zeitpunkt der Gabe |
| !'''Wiederholungsgabe<sup>3)</sup>''' | | !Wiederholungsgabe** |
| |- | | |- |
| |Cephalosporin Gruppe 3a<br /> | | |Cephalosporin Gruppe 3a<br /> |
| |Ceftriaxon<br /> | | |Ceftriaxon<br /> |
| |1 x 2g <span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br /> | | |1x2g i.v. |
| | |30 min |
| |Infusionsende 30 min vor Schnitt<br /> | | |Infusionsende 30 min vor Schnitt<br /> |
| |> 8 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | | |keine Dosiswiederholung |
| |- | | |- |
| |Fluorchinolon Gruppe 2<br /> | | |Fluorchinolon Gruppe 2<br /> |
| |Ciprofloxacin<br /> | | |Ciprofloxacin<br /> |
| |1 x 500<span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">p.</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">o</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">.</span> | | |1 x 400mg i.v. |
| | | |30-60 min |
| 1 x 400mg i.v. | | |90-120 min vor Schnitt*<br /> |
| |120 min vor Schnitt<sup>1)</sup> | | Infusionsende 30 min vor Schnitt |
| | | |8 h |
| Infusionsende 30 min vor Schnitt, Infusionsdauer 60 min | |
| |> 8 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | |
| |- | | |- |
| |Fluorchinolon Gruppe 3<br /> | | |Fluorchinolon Gruppe 3<br /> |
| |Levofloxacin<br /> | | |Levofloxacin<br /> |
| |1 x 500<span class="ve-pasteProtect" style="letter-spacing: | | |1 x 500mg p.o. |
| -.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">p.</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">o</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">.</span><br />
| | |30-60 min |
| |120 <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">min</span> vor Schnitt<sup>1)</sup><br /> | | |90-120 min vor Schnitt*<br /> |
| |> 12 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | | |keine Dosiswiederholung |
| |- | | |- |
| |Glykopetid<br /> | | |Glykopetid<br /> |
| |Vancomycin <sup>3)</sup><br /> | | |Vancomycin **<br /> |
| |1 x 1g <span class="ve-pasteProtect" style="letter-spacing:-.2pt" data-ve-attributes="{"style":"letter-spacing:-.2pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br /> | | |≤80 kg KG1 x 1g i.v. |
| |Infusionsende 30 min vor Schnitt, Infusionsdauer >60 min<sup>3)</sup><br /> | | 81-90 kg KG 1x1,5 g |
| |> 12 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | | ˃90 kg KG 1x2 g |
| | |60 min |
| | 90 min |
| | 2 h |
| | |Infusionsende 30 min vor Schnitt<br /> |
| | |8h |
| |- | | |- |
| |Folat-Antagonist<br /> | | |Folat-Antagonist<br /> |
| |Cotrimoxazol<br /> | | |Cotrimoxazol<br /> |
| |1 x 960<span class="ve-pasteProtect" style="letter-spacing: | | |1 x 960mg p.o. |
| -.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">p.</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">o</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">.</span><br />
| | |30-60 min |
| |120 <span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">min</span> vor Schnitt<sup>1)</sup><br /> | | |30-60 min vor Schnitt |
| |> 12 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | | |keine Dosiswiederholung |
| |- | | |- |
| |Lincosamid<br /> | | |Lincosamid<br /> |
| |Clindamycin<br /> | | |Clindamycin<br /> |
| |1 x 600<span class="ve-pasteProtect" style="letter-spacing: | | |1 x 600mg i.v. |
| -.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br />
| | ˃120 kg KG 1x 900 mg |
| | |20-30 min |
| |Infusionsende 30 min vor Schnitt<br /> | | |Infusionsende 30 min vor Schnitt<br /> |
| |> 6 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | | |6 h |
| |- | | |- |
| |Nitroimidazol<br /> | | |Nitroimidazol<br /> |
| |Metronidazol<br /> | | |Metronidazol<br /> |
| |1 x 500<span class="ve-pasteProtect" style="letter-spacing: | | |1 x 500 mg i.v. |
| -.05pt" data-ve-attributes="{"style":"letter-spacing:\n -.05pt"}">m</span><span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">g</span> <span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">i.</span><span class="ve-pasteProtect" style="letter-spacing:-.3pt" data-ve-attributes="{"style":"letter-spacing:-.3pt"}">v</span><span class="ve-pasteProtect" style="letter-spacing:-.25pt" data-ve-attributes="{"style":"letter-spacing:-.25pt"}">.</span><br />
| | ≥100-120 kg 1 x 1 g |
| | |20-30 min |
| |Infusionsende 30 min vor Schnitt<br /> | | |Infusionsende 30 min vor Schnitt<br /> |
| |> 8 h OP- <span class="ve-pasteProtect" style="letter-spacing:-.1pt" data-ve-attributes="{"style":"letter-spacing:-.1pt"}">D</span><span class="ve-pasteProtect" style="letter-spacing:-.05pt" data-ve-attributes="{"style":"letter-spacing:-.05pt"}">auer</span><br /> | | |8 h |
| |} | | |} |
| <sup>1)</sup> Maximaler Serumspiegel <span style="letter-spacing:.05pt">bei</span> <span style="letter-spacing:.05pt">normaler</span> enteraler <span style="letter-spacing:.05pt">Resorption</span> | | <small>* Maximaler Serumspiegel bei normaler enteraler Resorption</small> |
| | |
| <sup>2)</sup> „Imipenem 1g“ entspricht Imipenem 1g + Cilastatin 1g (= 2x 1Ampulle à 0,5g Imipenem + 0,5g Cilastatin)
| |
|
| |
|
| <sup>3)</sup> Infusionsdauer > 1 h, ansonsten <span style="letter-spacing: | | <small>** Infusionsdauer > 1 h, ansonsten Gefahr von „Red-Man-Syndrom“ (Hautrötung u. Schwellung im Kopf-Hals-Bereich, die wie eine Allergie imponieren kann)</small> |
| .05pt">Gefahr</span> von „Red-Man-Syndrom“ <span style="letter-spacing:
| |
| -.05pt">(Hautrötung</span> <span style="letter-spacing:.05pt">u.</span> <span style="letter-spacing:-.05pt">Schwellung</span> im <span style="letter-spacing:.05pt">Kopf-Hals-Bereich,</span> die <span style="letter-spacing:.05pt">wie</span> eine <span style="letter-spacing:
| |
| .05pt">Allergie</span> imponieren kann)
| |
|
| |
|
| <sup>4)</sup> In Abhängigkeit von <span style="letter-spacing:.05pt">der</span> Halbwertszeit <span style="letter-spacing:.05pt">bei</span> <span style="letter-spacing:.05pt">normaler</span> <span style="letter-spacing:.05pt">Nierenfunktion</span> | | <small>*** In Abhängigkeit von der Halbwertszeit bei normaler Nierenfunktion</small> |
|
| |
|
| <span style="color: #333333">Angaben Halbwertzeiten:</span> ''<span style="color: #333333">Mandell,</span> <span style="color: #333333"><span style="letter-spacing:-.05pt">Douglas</span> and <span style="letter-spacing:.05pt">Bennetts:</span> <span style="letter-spacing: | | <small>Angaben Halbwertzeiten: Mandell, Douglas and Bennetts: Principles and Practise of Infectious Disease. Elsevier Inc. 2009, Fachinformationen</small> |
| -.05pt">Principles</span> and Practise <span style="letter-spacing:
| |
| -.1pt">of</span> <span style="letter-spacing:.05pt">Infectious</span> Disease.</span> <small>Elsevier <span style="letter-spacing:
| |
| -.05pt">Inc.</span> <span style="letter-spacing:-.2pt">2009,</span> Fachinformationen</small>''
| |
| <br />
| |